Skip to main content

Expert commentary: SGLT2 inhibition in type 1 diabetes patients

John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)

More on this topic

Why nurses make the difference for diabetes

Learn more about the 2020 World Diabetes Day theme.

Image Credits